Penesyan Anahit, Gillings Michael, Paulsen Ian T
Department of Chemistry and Biomolecular Sciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW 2109, Australia.
Department of Biological Sciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW 2109, Australia.
Molecules. 2015 Mar 24;20(4):5286-98. doi: 10.3390/molecules20045286.
Bacterial resistance is a rapidly escalating threat to public health as our arsenal of effective antibiotics dwindles. Therefore, there is an urgent need for new antibiotics. Drug discovery has historically focused on bacteria growing in planktonic cultures. Many antibiotics were originally developed to target individual bacterial cells, being assessed in vitro against microorganisms in a planktonic mode of life. However, towards the end of the 20th century it became clear that many bacteria live as complex communities called biofilms in their natural habitat, and this includes habitats within a human host. The biofilm mode of life provides advantages to microorganisms, such as enhanced resistance towards environmental stresses, including antibiotic challenge. The community level resistance provided by biofilms is distinct from resistance mechanisms that operate at a cellular level, and cannot be overlooked in the development of novel strategies to combat infectious diseases. The review compares mechanisms of antibiotic resistance at cellular and community levels in the light of past and present antibiotic discovery efforts. Future perspectives on novel strategies for treatment of biofilm-related infectious diseases are explored.
随着我们有效的抗生素库逐渐减少,细菌耐药性对公众健康构成的威胁正在迅速升级。因此,迫切需要新的抗生素。历史上,药物研发一直专注于浮游培养中生长的细菌。许多抗生素最初是开发用于靶向单个细菌细胞的,在体外针对处于浮游生活方式的微生物进行评估。然而,到20世纪末,人们清楚地认识到,许多细菌在其自然栖息地中以称为生物膜的复杂群落形式存在,这包括人类宿主内的栖息地。生物膜生活方式为微生物提供了优势,例如增强了对包括抗生素挑战在内的环境压力的抵抗力。生物膜提供的群体水平耐药性不同于细胞水平的耐药机制,在开发对抗传染病的新策略时不能忽视。本文综述根据过去和现在的抗生素研发工作,比较了细胞水平和群体水平的抗生素耐药机制。探讨了治疗生物膜相关传染病新策略的未来前景。